Catalyst Brief

← Calendar

Readoutin 14d

Hangzhou Highlightll Pharmaceutical Co., Ltd — TLL-018

Phase 3 primary completion: A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis.

Date
Dec 2026
Type
Readout
Indication
Rheumatoid Arthritis

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.